NEWS

October, 2024

Renewal: Message from CEO & President

July 16, 2024

Targretin^® (Bexarotene) receives Marketing Authorisation in Hong Kong for Cutaneous T-Cell Lymphoma

June 24, 2024

Targretin^®was approved in Japan for an additional indication

July 5, 2023

Renewal: Message from CEO & President

February 1, 2016

Minophagen Pharmaceutical Got Approved for Targretin^®Capsules 75mg in Japan

April 2, 2012

Eisai and Minophagen Pharmaceutical Conclude License Agreement Concerning the Development and Commercialization of Cutaneous T-Cell Lymphoma Treatment Bexarotene in Asia, Oceania, the Middle East and Eastern Europe, etc.

March 30, 2011

Eisai and Minophagen Pharmaceutical Conclude Japan License Agreement For Cutaneous T-Cell Lymphoma Treatment Bexarotene

BackNumber

Get Adobe Reader

You need Adobe Reader to view and print the web pages.
Adobe Reader is freeware; you can download it from the download site.